Home Cart Sign in  
Chemical Structure| 1195768-06-9 Chemical Structure| 1195768-06-9

Structure of Dabrafenib Mesylate
CAS No.: 1195768-06-9

Chemical Structure| 1195768-06-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Dabrafenib Mesylate is a potent and selective inhibitor of Raf kinase, with IC50s of 0.6 nM for RafV600E and 5.0 nM for c-Raf.

Synonyms: GSK2118436 Mesylate; GSK 2118436B; Dabrafenib (mesylate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Dabrafenib Mesylate

CAS No. :1195768-06-9
Formula : C24H24F3N5O5S3
M.W : 615.67
SMILES Code : O=S(C1=C(F)C=CC=C1F)(NC2=CC=CC(C3=C(C4=NC(N)=NC=C4)SC(C(C)(C)C)=N3)=C2F)=O.CS(=O)(O)=O
Synonyms :
GSK2118436 Mesylate; GSK 2118436B; Dabrafenib (mesylate)
MDL No. :MFCD20922872
InChI Key :YKGMKSIHIVVYKY-UHFFFAOYSA-N
Pubchem ID :44516822

Safety of Dabrafenib Mesylate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Dabrafenib Mesylate

MAPK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02416232 - - - France ... More >> GSK Investigational Site Amiens Cedex, France, 80054 GSK Investigational Site Angers, France, 49100 GSK Investigational Site Bayonne cedex, France, 64109 GSK Investigational Site Besancon cedex, France, 25030 GSK Investigational Site Bobigny, France, 93000 GSK Investigational Site Bordeaux, France, 33075 GSK Investigational Site Boulogne-Billancourt, France, 92100 GSK Investigational Site Brest cedex, France, 29609 GSK Investigational Site Caen Cedex 9, France, 14033 GSK Investigational Site Chambray-Les-Tours, France, 37170 GSK Investigational Site Clermont-Ferrand cedex 1, France, 63003 GSK Investigational Site Creteil, France, 94010 GSK Investigational Site Dijon Cedex, France, 21079 GSK Investigational Site Grenoble cedex 9, France, 38043 GSK Investigational Site La Rochelle cedex 1, France, 17019 GSK Investigational Site Le Havre, France, 76083 GSK Investigational Site Le Mans, France, 72000 GSK Investigational Site Lille, France, 59037 GSK Investigational Site Limoges cedex, France, 87042 GSK Investigational Site Lorient, France, 56322 GSK Investigational Site Lyon Cedex 08, France, 69373 GSK Investigational Site Marseille Cedex 5, France, 13385 GSK Investigational Site Montpellier cedex 5, France, 34295 GSK Investigational Site Montpellier Cedex 5, France, 34298 GSK Investigational Site Mulhouse, France, 68100 GSK Investigational Site Nantes Cedex 1, France, 44093 GSK Investigational Site Nice, France, 06202 GSK Investigational Site Nimes, France, 30029 cedex 9 GSK Investigational Site Orleans Cedex 2, France, 45067 GSK Investigational Site Paris Cedex 10, France, 75475 GSK Investigational Site Paris, France, 75006 GSK Investigational Site Pau, France, 64000 GSK Investigational Site Pierre-Benite cedex, France, 69495 GSK Investigational Site Poitiers, France, 86021 GSK Investigational Site Pringy Cedex, France, 74374 GSK Investigational Site Reims Cedex, France, 51092 GSK Investigational Site Rennes Cedex, France, 35042 GSK Investigational Site Rouen, France, 76031 GSK Investigational Site Saint-Pierre, France, 97448 GSK Investigational Site Saint-Priest en Jarez, France, 42270 GSK Investigational Site Strasbourg Cedex, France, 67091 GSK Investigational Site Thionville, France, 57126 Cedex 1 GSK Investigational Site Toulouse Cedex 9, France, 31059 GSK Investigational Site Valence Cedex 9, France, 26953 GSK Investigational Site Vandoeuvre-Les-Nancy, France, 54511 GSK Investigational Site Villejuif cedex, France, 94805 Less <<
NCT01682083 Melanoma Phase 3 Active, not recruiting November 30, 2030 -
NCT01682083 - Active, not recruiting - -
NCT02083354 Cancer Phase 2 Active, not recruiting December 20, 2019 China, Guangdong ... More >> Novartis Investigative Site Guangzhou, Guangdong, China, 510060 China, Yunnan Novartis Investigative Site Kunming, Yunnan, China, 650106 China, Zhejiang Novartis Investigative Site Hangzhou, Zhejiang, China, 310022 China Novartis Investigative Site Beijing, China, 100036 Hong Kong Novartis Investigative Site Tuen Mun, Hong Kong Korea, Republic of Novartis Investigative Site Seoul, Korea, Republic of, 110-744 Novartis Investigative Site Seoul, Korea, Republic of, 120-752 Taiwan Novartis Investigative Site Kaohsiung, Taiwan, 807 Novartis Investigative Site Taipei, Taiwan, 100 Novartis Investigative Site Taoyuan County, Taiwan, 333 Thailand Novartis Investigative Site Bangkok, Thailand, 10320 Novartis Investigative Site Bangkok, Thailand, 10400 Novartis Investigative Site Songkla, Thailand, 90110 Less <<
NCT01738451 Cancer Phase 1 Completed - United States, Arizona ... More >> GSK Investigational Site Scottsdale, Arizona, United States, 85259 United States, Tennessee GSK Investigational Site Memphis, Tennessee, United States, 38120 GSK Investigational Site Nashville, Tennessee, United States, 37203 United States, Texas GSK Investigational Site San Antonio, Texas, United States, 78229 United States, Utah GSK Investigational Site Salt Lake City, Utah, United States, 84112-5550 Australia, Victoria GSK Investigational Site Heidelberg, Victoria, Australia, 3084 GSK Investigational Site Melbourne, Victoria, Australia, 3004 United Kingdom GSK Investigational Site London, United Kingdom, W1G 6AD Less <<
NCT01231568 Cancer Phase 1 Completed - United States, Arizona ... More >> GSK Investigational Site Scottsdale, Arizona, United States, 85259 United States, Michigan GSK Investigational Site Detroit, Michigan, United States, 48201 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 United States, Utah GSK Investigational Site Salt Lake City, Utah, United States, 84112 Less <<
NCT01336634 Cancer Phase 2 Active, not recruiting December 1, 2020 -
NCT02281760 BRAF V600E Mutation Phase 2 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01336634 - Active, not recruiting - -
NCT02447939 Melanoma Phase 1 Withdrawn(Change in strategy) December 2018 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.62mL

0.32mL

0.16mL

8.12mL

1.62mL

0.81mL

16.24mL

3.25mL

1.62mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories